Connecting you to content on EBSCOhost

Works matching IS 10109609 AND DT 2013 AND VI 27 AND IP 2

Results: 43

1

Untitled.

Published in:: WHO Drug Information, 2013, v. 27, n. 2, p. 109
Publication type:: Article

2

Case Study.

Published in:: 2013
Publication type:: Case Study

3

Quality and Safety of Medicines.

Published in:: WHO Drug Information, 2013, v. 27, n. 2, p. 97
Publication type:: Article

4

Varenicline and buproprion: revision to consumer information.

Published in:: WHO Drug Information, 2013, v. 27, n. 2, p. 109
Publication type:: Article

5

Magnesium sulphate during pregnancy: teratogenic effects.

Published in:: WHO Drug Information, 2013, v. 27, n. 2, p. 109
Publication type:: Article

6

Botulinum toxin type B: serious risks.

Published in:: WHO Drug Information, 2013, v. 27, n. 2, p. 108
Publication type:: Article

7

Thalidomide: risk of second primary malignancies.

Published in:: WHO Drug Information, 2013, v. 27, n. 2, p. 108
Publication type:: Article

8

Valproate-related products: risks during pregnancy.

Published in:: WHO Drug Information, 2013, v. 27, n. 2, p. 108
Publication type:: Article

9

Zolpidem products: lower doses recommended.

Published in:: WHO Drug Information, 2013, v. 27, n. 2, p. 107
Publication type:: Article

10

Aqueous cream: skin irritation.

Published in:: WHO Drug Information, 2013, v. 27, n. 2, p. 106
Publication type:: Article

11

Cilostazol-containing medicines: restricted use.

Published in:: WHO Drug Information, 2013, v. 27, n. 2, p. 106
Publication type:: Article

12

Cinacalcet: fatal paediatric hypocalcaemia.

Published in:: WHO Drug Information, 2013, v. 27, n. 2, p. 105
Publication type:: Article

13

Belatacept: acute graft rejection.

Published in:: WHO Drug Information, 2013, v. 27, n. 2, p. 105
Publication type:: Article

14

Incretin mimetics and GLP-1-based therapies: pancreatic risks.

Published in:: WHO Drug Information, 2013, v. 27, n. 2, p. 104
Publication type:: Article

15

Incretin mimetics: risk of pancreatitis and pancreatic duct metaplasia.

Published in:: WHO Drug Information, 2013, v. 27, n. 2, p. 104
Publication type:: Article

16

Ezogabine: retinal abnormalities and blue skin discoloration.

Published in:: WHO Drug Information, 2013, v. 27, n. 2, p. 103
Publication type:: Article

17

Osteoporosis treatments: atypical femur fracture.

Published in:: WHO Drug Information, 2013, v. 27, n. 2, p. 102
Publication type:: Article

18

Azithromycin: potential risk of QT prolongation.

Published in:: WHO Drug Information, 2013, v. 27, n. 2, p. 101
Publication type:: Article

19

First A1c test labelled for diagnosing diabetes.

Published in:: WHO Drug Information, 2013, v. 27, n. 2, p. 118
Publication type:: Article

20

Imatinib approved for leukaemia.

Published in:: WHO Drug Information, 2013, v. 27, n. 2, p. 117
Publication type:: Article

21

Oxycodone with abuse-deterrent properties approved.

Published in:: WHO Drug Information, 2013, v. 27, n. 2, p. 117
Publication type:: Article

22

Fluticasone furoate and vilanterol approved for chronic obstructive pulmonary disease.

Published in:: WHO Drug Information, 2013, v. 27, n. 2, p. 117
Publication type:: Article

23

Cysteamine bitartrate approved for rare genetic condition.

Published in:: WHO Drug Information, 2013, v. 27, n. 2, p. 116
Publication type:: Article

24

Dabrafenib, trametinib and companion diagnostic test for advanced skin cancer.

Published in:: WHO Drug Information, 2013, v. 27, n. 2, p. 116
Publication type:: Article

25

Erlotinib and diagnostic test approved for non-small cell lung cancer.

Published in:: WHO Drug Information, 2013, v. 27, n. 2, p. 115
Publication type:: Article

26

Radium dichloride approved for advanced prostate cancer.

Published in:: WHO Drug Information, 2013, v. 27, n. 2, p. 115
Publication type:: Article

27

Golimumab approved for ulcerative colitis.

Published in:: WHO Drug Information, 2013, v. 27, n. 2, p. 115
Publication type:: Article

28

Nimodipine oral solution approved for subarachnoid haemorrhage.

Published in:: WHO Drug Information, 2013, v. 27, n. 2, p. 114
Publication type:: Article

29

Lenalidomide: approved for myelodysplastic syndromes.

Published in:: WHO Drug Information, 2013, v. 27, n. 2, p. 114
Publication type:: Article

30

Vismodegib approved for basal cell carcinoma.

Published in:: WHO Drug Information, 2013, v. 27, n. 2, p. 114
Publication type:: Article

31

Autologous chondrocyte implantation approved for cartilage defects.

Published in:: WHO Drug Information, 2013, v. 27, n. 2, p. 113
Publication type:: Article

32

Idebenone: voluntary withdrawal.

Published in:: WHO Drug Information, 2013, v. 27, n. 2, p. 113
Publication type:: Article

33

Dabigatran etexilate: updated contraindications.

Published in:: WHO Drug Information, 2013, v. 27, n. 2, p. 112
Publication type:: Article

34

Tetrazepam-containing medicines: suspension.

Published in:: WHO Drug Information, 2013, v. 27, n. 2, p. 112
Publication type:: Article

35

Strontium ranelate: restricted use.

Published in:: WHO Drug Information, 2013, v. 27, n. 2, p. 112
Publication type:: Article

36

Levothyroxine: licence suspension.

Published in:: WHO Drug Information, 2013, v. 27, n. 2, p. 111
Publication type:: Article

37

Black triangle for medicines subject to additional monitoring.

Published in:: WHO Drug Information, 2013, v. 27, n. 2, p. 111
Publication type:: Article

38

Counterfeit antimalarial medicines: detection tool.

Published in:: WHO Drug Information, 2013, v. 27, n. 2, p. 110
Publication type:: Article

39

Recommended influenza virus vaccine composition: 2013-2014 Northern hemisphere season.

Published in:: WHO Drug Information, 2013, v. 27, n. 2, p. 110
Publication type:: Article

40

New guide to improve procurement performance.

Published in:: WHO Drug Information, 2013, v. 27, n. 2, p. 129
Publication type:: Article

41

Consortium to test kala-azar treatments in East Africa.

Published in:: WHO Drug Information, 2013, v. 27, n. 2, p. 129
Publication type:: Article

42

The International Pharmacopoeia.

Published in:: WHO Drug Information, 2013, v. 27, n. 2, p. 119
Publication type:: Article

43

ATC/DDD Classification.

Published in:: WHO Drug Information, 2013, v. 27, n. 2, p. 130
Publication type:: Article